SPY319.34+7.98 2.56%
DIA271.54+8.21 3.12%
IXIC9,814.08+198.27 2.06%
News
MNTA
--
0.00%
--
Why Is Momenta (MNTA) Down 0.6% Since Last Earnings Report?
Zacks · 5h ago
Is Momenta Pharmaceuticals' Stock a Buy?
Motley Fool · 3d ago
Edited Transcript of MNTA earnings conference call or presentation 7-May-20 12:30pm GMT
Q1 2020 Momenta Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents · 3d ago
Hedge Funds Arent Done Buying Momenta Pharmaceuticals, Inc. (MNTA)
Insider Monkey · 4d ago
Efgartigimods Positive Data Is Good News for Momentas Nipocalimab
SmarterAnalyst · 05/29 23:25
Momenta Pharmaceuticals Could Finally Make a Big Upside Breakout
TheStreet.com · 05/13 16:54
Biotech's Golden Moment As Healthcare Attracts Investors
Seeking Alpha - Article · 05/12 13:31
Analysts Just Shipped A Stunning Upgrade To Their Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Estimates
Simply Wall St. · 05/12 12:55
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig Wheeler on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 20:07
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Simply Wall St. · 05/09 15:34
H.C. Wainwright Reiterates Buy on Momenta Pharmaceuticals, Raises Price Target to $40
H.C. Wainwright reiterates Momenta Pharmaceuticals (NASDAQ:MNTA) with a Buy and raises the price target from $36 to $40.
Benzinga · 05/08 13:28
Momenta Pharmaceuticals Inc (MNTA) Q1 2020 Earnings Call Transcript
Motley Fool · 05/08 05:31
Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results
GlobeNewswire · 05/07 12:00
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.)
Benzinga · 05/07 11:42
Momenta Pharmaceuticals Q1 EPS $(0.340) Beats $(0.480) Estimate, Sales $8.700M Beat $4.330M Estimate
Momenta Pharmaceuticals (NASDAQ:MNTA) reported quarterly losses of $(0.340) per share which beat the analyst consensus estimate of $(0.480) by 29.17 percent. This is a 26.09 percent increase over losses of $(0.460) per
Benzinga · 05/07 11:25
Analysts Estimate Momenta Pharmaceuticals (MNTA) to Report a Decline in Earnings: What to Look Out for
Zacks · 04/30 17:33
Does Regeneron Pharmaceuticals� Winning Streak Signal Irrational Exuberance?
MotleyFool.com · 04/24 10:30
Biotech Melt-Up
Seeking Alpha - Article · 04/23 13:00
Momenta Pharmaceuticals Announces Date of First Quarter 2020 Financial Results Conference Call and Webcast
GlobeNewswire · 04/23 13:00
Is Momenta Pharmaceuticals, Inc.'s (NASDAQ:MNTA) CEO Salary Justified?
Simply Wall St. · 04/13 16:00